Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in
patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine
the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used
in phase 2.